Table 4.

Summary of mean inspiratory flow (V_T/T_I; mL/sec ± SEM) during baseline, hypoxia (HX), hypercapnia (HC) and hypoxia + hypercapnia (HX + HC) in all treatment groups. Groups were: Sham (WT: n=8; MT: n=9), PCPA (WT: n=3; MT: n=3), PCPA + Methy (WT: n=3; MT: n=3), MSX-3 (WT: n=3; MT: n=3), PCPA + MSX-3 (WT: n=3; MT: n=3), and Apo + MSX-3 + Methy (WT: n=3; MT: n=3). Significance was accepted at p < 0.05; 3 = Sham MT vs. treatment group MT.

Mean Inspiratory Flow	Baseline	HX	HC	HX + HC
Sham WT	13 ± 4	18 ± 4	26 ± 6	29 ± 7
Sham MT	9 ± 0.6	16 ± 2	23 ± 3	24 ± 3
PCPA WT	16 ± 4	17 ± 4	26 ± 5	28 ± 6
PCPA MT	12 ± 0.5	14 ± 0.4	27 ± 2	27 ± 3
PCPA + Methy WT	14 ± 1	16 ± 1	32 ± 2	31 ± 2
PCPA + Methy MT	13 ± 1	15 ± 2	31 ± 2	32 ± 1
MSX-3 WT	17 ± 1	18 ± 0.6	27 ± 0.2	28 ± 0.6
MSX-3 MT	14 ± 2	15 ± 0.8	26 ± 1	28 ± 2
MSX-3 + PCPA WT	19 ± 2	18 ± 1	33 ± 1	33 ± 1
MSX-3 + PCPA MT	18 ± 0.8	17 ± 0.2	33 ± 1	34 ± 0.8
Apocynin + MSX-3 + Methy WT	18 ± 0.4	22 ± 1	37 ± 2	37 ± 3
Apocynin + MSX-3 + Methy MT	16 ± 2	18 ± 0.8	36 ± 43	39 ± 43